BR112022021592A2 - Anticorpo anti-igsf1 e uso do mesmo - Google Patents
Anticorpo anti-igsf1 e uso do mesmoInfo
- Publication number
- BR112022021592A2 BR112022021592A2 BR112022021592A BR112022021592A BR112022021592A2 BR 112022021592 A2 BR112022021592 A2 BR 112022021592A2 BR 112022021592 A BR112022021592 A BR 112022021592A BR 112022021592 A BR112022021592 A BR 112022021592A BR 112022021592 A2 BR112022021592 A2 BR 112022021592A2
- Authority
- BR
- Brazil
- Prior art keywords
- igsf1
- antibody
- present
- overexpressed
- cells
- Prior art date
Links
- 101150009156 IGSF1 gene Proteins 0.000 abstract 7
- 102100022514 Immunoglobulin superfamily member 1 Human genes 0.000 abstract 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000005202 lung cancer Diseases 0.000 abstract 3
- 208000020816 lung neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000008595 infiltration Effects 0.000 abstract 2
- 238000001764 infiltration Methods 0.000 abstract 2
- 230000004614 tumor growth Effects 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000011577 humanized mouse model Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000005087 mononuclear cell Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Abstract
ANTICORPO ANTI-IGSF1 E USO DO MESMO. A presente invenção se refere a um novo anticorpo que se liga especificamente a IGSF1 e a uma composição farmacêutica para prevenção ou tratamento de câncer, compreendendo o mesmo como ingrediente ativo. Especificamente, a presente invenção fornece um anticorpo que se liga ao terminal C de IGSF1. O anticorpo anti-IGSF1 de acordo com a presente invenção exibiu alta especificidade e alta capacidade de ligação ao IGSF1. O anticorpo anti-IGSF1 de acordo com a presente invenção aumentou a infiltração de células imunes nos esferoides quando os esferoides de células de câncer de pulmão em que IGSF1 é superexpresso foram cocultivados com células mononucleares periféricas humanas. Além disso, o anticorpo anti-IGSF1 de acordo com a presente invenção inibiu o crescimento tumoral em um camundongo humanizado transplantado com células de câncer de pulmão humano em que a IGSF1 é superexpressa e aumentou a expressão de citocinas em tecidos tumorais. Através dos resultados acima, foi confirmado que o anticorpo anti-IGSF1 pode inibir o crescimento tumoral aumentando a infiltração de células imunes em tecidos de câncer de pulmão em que a expressão de IGSF1 é aumentada, e a resposta imune. Portanto, o anticorpo anti-IGSF1 pode ser utilizado como um agente anticâncer para tratar eficazmente o câncer no qual a IGSF1 é superexpressa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2021/011139 WO2023022271A1 (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021592A2 true BR112022021592A2 (pt) | 2023-03-14 |
Family
ID=85223221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021592A BR112022021592A2 (pt) | 2021-08-20 | 2021-08-20 | Anticorpo anti-igsf1 e uso do mesmo |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR20240046103A (pt) |
| CN (1) | CN116635418A (pt) |
| AU (1) | AU2021437023A1 (pt) |
| BR (1) | BR112022021592A2 (pt) |
| CA (1) | CA3177927A1 (pt) |
| WO (1) | WO2023022271A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048992B2 (en) * | 2005-02-28 | 2011-11-01 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
| CN107532199B (zh) | 2014-07-29 | 2021-10-22 | 威马克生物有限公司 | 与间质上皮转化因子抑制剂有关的感受性预测用新型生物标志物及其用途 |
-
2021
- 2021-08-20 WO PCT/KR2021/011139 patent/WO2023022271A1/ko active Application Filing
- 2021-08-20 KR KR1020237005825A patent/KR20240046103A/ko unknown
- 2021-08-20 AU AU2021437023A patent/AU2021437023A1/en active Pending
- 2021-08-20 BR BR112022021592A patent/BR112022021592A2/pt unknown
- 2021-08-20 CN CN202180048750.4A patent/CN116635418A/zh active Pending
- 2021-08-20 CA CA3177927A patent/CA3177927A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240046103A (ko) | 2024-04-08 |
| AU2021437023A1 (en) | 2023-03-09 |
| CN116635418A (zh) | 2023-08-22 |
| CA3177927A1 (en) | 2023-02-20 |
| WO2023022271A1 (ko) | 2023-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis | |
| Ding et al. | CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis | |
| Salerno et al. | Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia | |
| Bell et al. | Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations | |
| Qin et al. | PI3Kgamma inhibitor attenuates immunosuppressive effect of poly (l‐Glutamic Acid)‐Combretastatin A4 conjugate in metastatic breast cancer | |
| BR112021023901A2 (pt) | Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer | |
| BR112021015098A2 (pt) | Inibidores de enpp1 e métodos de modulação da resposta imune | |
| Basha et al. | Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors | |
| Younes et al. | A global, randomized, placebo-controlled, phase 3 study of ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with previously untreated non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| Li et al. | Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| KR101539205B1 (ko) | 세쿠리닌을 유효성분으로 포함하는 암 줄기세포 분화 유도용 조성물 및 이의 용도 | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| Yi et al. | Pyrotinib sensitizes 5-fluorouracil-resistant HER2+ breast cancer cells to 5-fluorouracil | |
| Lin et al. | (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer | |
| AU2016319111B2 (en) | Azophenols as ERG oncogene inhibitors | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| BR112022021592A2 (pt) | Anticorpo anti-igsf1 e uso do mesmo | |
| EA202190753A1 (ru) | Состав, содержащий озонированное масло, для лечения опухоли | |
| Wang et al. | CSL regulates AKT to mediate androgen independence in prostate cancer progression | |
| Bales et al. | Targeted treatment of differentiated and medullary thyroid cancer | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer |